IRVINE, CA, and HERSTAL, BELGIUM – February 12, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, February 26, 2025.
| Title: | Mdxhealth Presents Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call and Webcast |
| Speakers: | Michael K. McGarrity, Chief Executive Officer Ron Kalfus, Chief Financial Officer |
| Date: | February 26, 2025 |
| Time: | 4:30pm ET/ 22:30 CET |
| Conference Call Dial-in Details: | United States: 1-844-825-9789 Belgium: 0800 38 961 The Netherlands: 0800 94 94 506 United Kingdom: 0808 238 9064 |
| Conference ID: | 10196702 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1706814&tp_key=e01537d9e2 |
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.
About Mdxhealth
Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
| MDxHealth This email address is being protected from spambots. You need JavaScript enabled to view it. | |
| LifeSci Advisors (IR & PR) US: +1 949 271 9223 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$1.60 |
| Daily Change: | 0.06 3.56 |
| Daily Volume: | 15,252 |
| Market Cap: | US$79.200M |
February 26, 2025 January 13, 2025 November 06, 2024 October 14, 2024 September 25, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
